Clinical Trials
926 trialsChemotherapy and Radiation Therapy With or Without Metformin Hydrochloride in Treating Patients With Stage III Non-small Cell Lung Cancer
NRG Oncology
Neoadjuvant Nivolumab With CCR2/5-inhibitor or Anti-IL-8) for Non-small Cell Lung Cancer (NSCLC) or Hepatocellular Carcinoma (HCC)
Icahn School of Medicine at Mount Sinai
TARSEQ
University Hospital, Limoges
MK-3475-01C
Merck Sharp & Dohme LLC
GFPC 06-2018
Centre Francois Baclesse
DARWINII
University College, London
A Study of Tiragolumab in Combination With Atezolizumab in Chemotherapy-Naïve Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Genentech, Inc.
NAVIGATE
Bayer
National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer
University of Birmingham
FLT3
Montefiore Medical Center
REPAINT
Albert Einstein College of Medicine
A Study of Tucidinostat Combined With Tislelizumab as First-line Treatment in Advanced NSCLC
Chipscreen Biosciences, Ltd.
Pembrolizumab in Preventing Lung Cancer in Patients With Stage I-II Non-Small Cell Lung Cancer or High-Risk Pulmonary Nodules, the IMPRINT-Lung Study
M.D. Anderson Cancer Center
ASTEROID
Vastra Gotaland Region
SPRINT
Montefiore Medical Center
IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC
IO Biotech
ATLANTIC
AstraZeneca
Nivolumab With or Without Ipilimumab or Chemotherapy in Treating Patients With Previously Untreated Stage I-IIIA Non-small Cell Lung Cancer
M.D. Anderson Cancer Center
358
Brown University
GeoMETry-C
Novartis
TRADE-hypo
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer
Pfizer
Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations (TROPION-Lung05)
Daiichi Sankyo
TOP 1501
Duke University
Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors
Seagen Inc.
Priming Immunotherapy in Advanced Disease With Radiation
University of Kentucky
A Study of SHR-1210 in Combination With Apatinib in Advanced Non-Small Cell Lung Cancer(NSCLC)
Jiangsu HengRui Medicine Co., Ltd.
Bevacizumab Combined With Double Doses of Icotinib in Advanced NSCLC Patients With EGFR L858R Mutation
Tianjin Medical University Cancer Institute and Hospital
Efficacy, Safety, and Pharmacodynamics of Tislelizumab Monotherapy and Multiple Tislelizumab-based Immunotherapy Combinations in Participants With Resectable Non-Small Cell Lung Cancer
BeOne Medicines
Combination of Osimertinib and Aspirin to Treat EGFR Mutation NSCLC Patients
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
A Study of Local Ablative Therapy (LAT) in People With Non-Small Cell Lung Cancer (NSCLC)
Memorial Sloan Kettering Cancer Center
A Study Comparing Sotorasib With Durvalumab in People With Non-Small Cell Lung Cancer (NSCLC)
Memorial Sloan Kettering Cancer Center
Balise
Eli Lilly and Company
Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC)
Big Ten Cancer Research Consortium
A Study of Dabrafenib in Combination With Trametinib in Chinese Patients With BRAF V600E Mutant Metastatic NSCLC
Novartis
AURA17
AstraZeneca
BLOSSOM
Samsung Medical Center
Hybrid Dose-fraction Radiotherapy for Metastatic Non-small Cell Lung Cancer
Anhui Provincial Hospital
Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies
Revolution Medicines, Inc.
A Study of Gimistotug (BGB-A445) in Combination With Other Investigational Agents in Participants With Non-Small Cell Lung Cancer
BeOne Medicines
RTEP7
Centre Henri Becquerel
Phase II Study of Durvalumab ,Doxorubicin, and Ifosfamide in Pulmonary Sarcomatoid Carcinoma
Seoul National University Hospital
A Study of Amivantamab and Lazertinib in People With Non-Small Cell Lung Cancer (NSCLC)
Memorial Sloan Kettering Cancer Center
A Trial of Integrating SBRT With Targeted Therapy in Stage IV Oncogene-driven NSCLC
Massachusetts General Hospital
A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ®) in Patients With Ovarian Cancer and Selected Solid Tumors
I-Mab Biopharma US Limited
A Study to Evaluate Participant and Healthcare Professional Reported Preference for Subcutaneous Atezolizumab Compared With Intravenous Atezolizumab Formulation in Participants With Non-Small Cell Lung Cancer
Hoffmann-La Roche
TELMA
Fundación GECP
PRIMM
University Medical Centre Maribor
MK-3475-01B
Merck Sharp & Dohme LLC
Platinum Doublet Chemotherapy and Proton Beam Radiation Therapy in Treating Patients With Stage II-III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
Mayo Clinic